Current disease status-First occurrence of the lymphoma - Page 3 of 14 Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the lymphoma Posts on Medivizor

Evaluating combined modality treatment for young adults with Hodgkin lymphoma

Evaluating combined modality treatment for young adults with Hodgkin lymphoma

Posted by on Dec 7, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the safety and effectiveness of combined modality treatment for young adults with classical Hodgkin lymphoma (cHL). This study concluded that this treatment approach was well-tolerated and effective for these patients. Some background Chemotherapy regimens for pediatric patients with cHL are different from...

Read More

Evaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment

Evaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment

Posted by on Nov 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with primary mediastinal large B-cell lymphoma (PMBCL) that has come back or stopped responding to treatment. This study concluded that pembrolizumab was safe and effective for these patients. Some background PMBCL is one rare and aggressive type...

Read More

What factors can predict the success of stem cell transplantation for patients with lymphoma?

What factors can predict the success of stem cell transplantation for patients with lymphoma?

Posted by on Nov 3, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some...

Read More

Evaluating brentuximab vedotin for patients with relapsed or unresponsive Hodgkin lymphoma after SCT

Evaluating brentuximab vedotin for patients with relapsed or unresponsive Hodgkin lymphoma after SCT

Posted by on Oct 27, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of brentuximab vedotin (Adcetris) to chemotherapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding after a stem cell transplant (SCT). This study concluded that patients treated with brentuximab vedotin had better outcomes compared to patients in the...

Read More

Lymphoma transformation risk in patients with advanced follicular lymphoma

Posted by on Sep 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the frequency of lymphoma transformation in patients with advanced-stage follicular lymphoma (FL) after treatment with BR (bendamustine, rituximab). This study concluded these patients might be at risk for lymphoma transformation after initial treatment. Some background FL is the second most common type of...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Fertility options for female patients with lymphoma or leukemia

Fertility options for female patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed different options to preserve or restore fertility in female patients with lymphoma or leukemia. Some background Impaired reproductive function is one possible side effect of aggressive chemotherapy and radiotherapy for cancer. In severe cases, intensive anti-cancer treatment can lead to fertility loss. 7 to 9% of...

Read More

Can immune profiling help predict outcomes for patients with NHL after a stem cell transplant?

Can immune profiling help predict outcomes for patients with NHL after a stem cell transplant?

Posted by on Aug 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of filgrastim (Neupogen) treatment with versus without plerixafor (Mozobil) in patients with B-cell non-Hodgkin's lymphoma (NHL) after a stem cell transplant. The authors concluded that certain immune cell biomarkers were associated with poorer long-term survival for these patients. Some...

Read More

Evaluating different doxorubicin doses for patients with diffuse large B-cell lymphoma

Evaluating different doxorubicin doses for patients with diffuse large B-cell lymphoma

Posted by on Aug 21, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated three different chemotherapy regimens with varying doses of doxorubicin (Adriamycin) for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CEOP70 could be safely used instead of R-CHOP50, while R-CEOP90 may be recommended for younger patients. Some background DLBCL is one of the most...

Read More